Skip to content

Study · Non-randomized trial · n = 62 · 2022

2 results

A novel approach to patients with schizophrenia and type 2 diabetes showing low treatment compliance

Argitis P, Karampas A, Bringiotti P, Karavia S, Pikou O, Kakavitsas F

European psychiatry : the journal of the Association of European Psychiatrists1 Sept 2022

PMCIDPMC9568080 (opens in a new tab)PepBankPUB-97278155
Download PDFSource pageAsk about this study
Jump to 2 results

Summary

Introduction Patients with schizophrenia usually demonstrate low compliance to medication. This could be a component of the disorder or a fact that they are not being properly cared. Objectives To prevent this in, we tried to treat these patients with long term action antidiabetic agents, in order to achieve better compliance. Methods HbA1C measurements of patients suffering from schizophrenia and at the same time receiving oral antidiabetic treatment were conducted. 62 patients were found that fell under the criteria of non regulated type 2 diabetes and at the same time presented less than 70% complied with their antidiabetic pharmaceutical treatment. We modified the antidiabetic treatment of these patients, with the introduction of dulaglutide. Results Without intervening with their nutritional habits there was a decline in HbA1C measurements from the average rate of 9,4% to the average rate of 7,6%, as well as an average 6,31% reduction of their body weight. Conclusions Due to the improvement of the general medical condition of these patients, the answer to the question whether these patients should be treated with a long term antidiabetic medicines, is positive. The arrival of new long term action antidiabetic medicines in the near future, promises to improve the life quality of schizophrenic patients furthermor. Disclosure No significant relationships.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with schizophrenia and uncontrolled T2D, HbA1c decreased after introduction of dulaglutide.

    In plain wordsIn patients with schizophrenia and diabetes, blood sugar decreased after dulaglutide treatment compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c
    Study

    n = 62

    Comparator
    Pretreatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c
    9.4%
    average before dulaglutide
    HbA1c
    7.6%
    average after dulaglutide

    Source sentences

    Summary
    Without intervening with their nutritional habits there was a decline in HbA1C measurements from the average rate of 9,4% to the average rate of 7,6%, as well as an average 6,31% reduction of their body weight.
    2 context sentences
    Summary · context
    62 patients were found that fell under the criteria of non regulated type 2 diabetes and at the same time presented less than 70% complied with their antidiabetic pharmaceutical treatment.
    Summary · context
    We modified the antidiabetic treatment of these patients, with the introduction of dulaglutide.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with schizophrenia and uncontrolled T2D, body weight decreased after introduction of dulaglutide.

    In plain wordsIn patients with schizophrenia and diabetes, body weight decreased after dulaglutide treatment compared with pretreatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    n = 62

    Comparator
    Pretreatment
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Body weight reduction
    6.31%
    average after dulaglutide

    Source sentences

    Summary
    Without intervening with their nutritional habits there was a decline in HbA1C measurements from the average rate of 9,4% to the average rate of 7,6%, as well as an average 6,31% reduction of their body weight.
    2 context sentences
    Summary · context
    62 patients were found that fell under the criteria of non regulated type 2 diabetes and at the same time presented less than 70% complied with their antidiabetic pharmaceutical treatment.
    Summary · context
    We modified the antidiabetic treatment of these patients, with the introduction of dulaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.